|Veröffentlichungsdatum||9. Sept. 2004|
|Eingetragen||29. Sept. 2003|
|Prioritätsdatum||3. Febr. 2003|
|Auch veröffentlicht unter||EP2366425A1, US7489969, US7729771, US8010204, US8538542, US20040172084, US20040172085, US20040172086, US20060229685, US20080021512, US20100168815, US20110282411, US20140172052|
|Veröffentlichungsnummer||10675818, 675818, US 2004/0176812 A1, US 2004/176812 A1, US 20040176812 A1, US 20040176812A1, US 2004176812 A1, US 2004176812A1, US-A1-20040176812, US-A1-2004176812, US2004/0176812A1, US2004/176812A1, US20040176812 A1, US20040176812A1, US2004176812 A1, US2004176812A1|
|Erfinder||Mark Knudson, Richard Wilson, Katherine Tweden, Timothy Conrad|
|Ursprünglich Bevollmächtigter||Beta Medical, Inc.|
|Zitat exportieren||BiBTeX, EndNote, RefMan|
|Patentzitate (76), Referenziert von (153), Klassifizierungen (18), Juristische Ereignisse (2)|
|Externe Links: USPTO, USPTO-Zuordnung, Espacenet|
 The present application is a continuation-in-part application of U.S. patent application Ser. No. 10/358,093 filed Feb. 3, 2003 and entitled “Method and Apparatus for Treatment of Gastroesophageal Disease (GERD)”. The present application discloses and claims subject matter disclosed in the following commonly assigned and copending U.S. patent applications filed on the same date as the present application and in the name of the same inventors: U.S. patent application Ser. No. ______, not yet assigned, entitled “Nerve Stimulation And Conduction Block Therapy”, having Attorney Docket No. 14283.1USI3 and U.S. patent application Ser. No. ______, not yet assigned, entitled “Nerve Conduction Block Treatment”, having Attorney Docket No. 14283.1USI1.
 1. Field of the Invention
 This invention pertains to treatments of disorders associated, at least in part, with neural activity. These may include, without limitation, gastrointestinal, pancreo-biliary, cardio-respiratory and central nervous system disorders (including neurological and psychiatric, psychological and panic disorders). More particularly, this invention pertains to treatment of such disorders through management of neural impulse stimulation and blocking.
 2. Description of the Prior Art
 A. Functional Gastrointestinal Disorders (FGIDs)
 Functional Gastrointestinal Disorders (FGIDs) are a diagnostic grouping having diagnostic criteria based on symptomatology, because the pathophysiology of these diseases is multifactorial with some pathophysiologic mechanisms in common. FGIDs are thought to be due to altered autonomic nervous system balance and to be pathophysiological combinations of: (1) abnormal GI motility; (2) visceral hypersensitivity; and, (3) brain-gut interactions. Tougas, “The Autonomic Nervous System in Functional Bowel Disorders”, Gut, Vol. 47 (Suppl IV), pp. iv78-iv80 (2000) and Drossman, “Rome II: A Multinational Consensus Document on Gastrointestinal Disorders—The Functional Gastrointestinal Disorders and the Rome II Process”, Gut, Vol. 45 (Suppl II):II1-II5 (1999). The FGIDs of interest to the present invention are functional dyspepsia (dysmotility-like) and irritable bowel syndrome (IBS).
 1. Functional Dyspepsia (Dysmotility-Like)
 Functional dyspepsia (dysmotility-like), is diagnosed when a patient's symptoms, in the absence of other organic disease likely to explain the symptoms, include persistent or recurrent pain or discomfort centered in the upper abdomen that may be accompanied by upper abdominal fullness, early satiety, bloating or nausea. Talley et al., “Rome II: A Multinational Consensus Document on Gastrointestinal Disorders—Functional Gastroduodenal Disorders” Gut, Vol. 45 (Suppl II), pp. I37-II42 (1999).
 A spectrum of dysmotilities has been documented in patients with functional dyspepsia. These include delayed gastric emptying of solids and liquids, reduced vagal tone, gastric dysrhythmias and impaired gastric accommodation. Furthermore, some studies have found good correlation between symptoms and indices of dysmotility, while others have not. Stanghellini V, et al., “Delayed Gastric Emptying of Solids in Patients with Functional Dyspepsia”, Gastroenterol, (1996) 110:1036-1042. Undeland K A, et al., “Wide Gastric Antrum and Low Vagal Tone in Patients with Diabetes Mellitus Type 1 Compared to Patients with Functional Dyspepsia and Healthy Individuals”, Dig Dis Sci, (1996) 41:9-16. Tack J, et al., “Role of Impaired Gastric Accommodation to a Meal in Functional Dyspepsia”, Gastroenterol, (1998) 115:1346-1352. Wilmer A, et al., “Ambulatory Gastrojejunal Manometry in Severe Motility-like Dyspepsia: Lack of Correlation between Dysmotility, Symptoms and Gastric Emptying”, Gut, (1998) 42:235-242. Tack J, et al., “Symptom Pattern and Gastric Emptying Rate Assessed by the Octanoic Acid Breath Test in Functional Dyspepsia” [abstract]. Gastroenterol, (1998) 114:A301. Cuomo R, et al., “Functional Dyspepsia Symptoms, Gastric Emptying and Satiety Provocation Test: Analysis of Relationships”, Scand J Gastroenterol, (2001) 36:1030-1036. Sarnelli G, et al., “Symptoms Associated with Impaired Gastric Emptying of Solids and Liquids in Functional Dyspepsia”, Am J Gastroenterol, (2003) 98:783-788.
 2. Irritable Bowel Syndrome (IBS)
 The second FGID of interest, IBS, is diagnosed when a patient's symptoms include persistent abdominal pain or discomfort, in the absence of other explanatory organic disease, along with at least two of the following: relief of pain with defecation, onset of symptoms associated with a change in frequency of stools and/or onset of symptoms associated with a change in appearance/form of stools. Thompson WG, et al., “Rome II: A Multinational Consensus Document on Gastrointestinal Disorders—Functional Bowel Disorders and Functional Abdominal Pain”, Gut, (1999);45(Suppl II):II43-II47.
 In addition to colonic dysmotility, a number of other GI motility abnormalities have been identified, including delayed gastric emptying, gastroparesis, and small intestine motility abnormalities. Vassallo M J, et al., “Colonic Tone and Motility in Patients with Irritable Bowel Syndrome”, Mayo Clin Proc, (1992);67:725-731. Van Wijk H J, et al., “Gastric Emptying and Dyspeptic Symptoms in the Irritable Bowel Syndrome”, Scand J Gastroenterol, (1992);27:99-102. Evans P R, et al., “Gastroparesis and Small Bowel Dysmotility in Irritable Bowel Syndrome”, Dig Dis Sci (1997);42:2087-2093. Cann P A, et al. “Irritable Bowel Syndrome: Relationship of Disorders in the Transit of a Single Solid Meal to Symptoms Patterns”, Gut, (1983);24:405-411. Kellow J E, et al., “Dysmotility of the Small Intestine in Irritable Bowel Syndrome”, Gut, (1988);29:1236-1243. Evans PR, et al., “Jejunal Sensorimotor Dysfunction in Irritable Bowel Syndrome: Clinical and Psychosocial Features”, Gastroenterol, (1996);110:393-404. Schmidt T, et al., “Ambulatory 24-Hour Jejunal Motility in Diarrhea-Predominant Irritable Bowel Syndrome”, J Gastroenterol, (1996);31:581-589. Simren M, et al., “Abnormal Propagation Pattern of Duodenal Pressure Waves in the Irritable Bowel Syndrome (IBS)”, Dig Dis Sci, (2000);45:2151-2161.
 A related finding is that patients with constipation-predominant IBS have evidence of decreased vagal tone, while diarrhea-predominant IBS is associated with evidence of increased sympathetic activity. Aggarwal A, et al., “Predominant Symptoms in Irritable Bowel Syndrome Correlate with Specific Autonomic Nervous system Abnormalities”, Gastroenterol, (1994); 106:945-950.
 There is no cure for IBS. Treatments include supportive palliative care (antidiarrheals, dietary modification and counseling).
 A recently approved drug to treat selected patients with FGIDs is tegaserod maleate sold under the tradename “Zelnorm®” by Novartis Pharmaceuticals Corp., East Hanover, N.J., USA. The product literature on Zelnorm recognizes the enteric nervous system is a key element in treating IBS. The literature suggests Zelnorm® acts to enhance basal motor activity and to normalize impaired motility. Novartis product description, Zelnorm®, July 2002 (T2002-19). Zelnorm's approved use is limited to females with constipation-related IBS. It is for short-term use only.
 B. Gastroparesis
 The third disease indication discussed here, gastroparesis (or delayed gastric emptying) is associated with upper GI symptoms such as nausea, vomiting fullness, bloating and early satiety. Gastroparesis can be caused by many underlying conditions. The most important, because of chronicity and prevalence, are diabetes, idiopathic and post-surgical. Hombuckle K, et al. “The Diagnosis and Work-Up of the Patient with Gastroparesis”, J Clin Gastroenterol, (2000);30: 117-124. GI dysmotility in the form of delayed gastric emptying is, by definition, present in these patients.
 In patients with Type 1 diabetes mellitus and delayed gastric emptying, there appears to be a relationship between delayed gastric emptying and low vagal tone. Merio R, et al., “Slow Gastric Emptying in Type 1 Diabetes: Relation to Autonomic and Peripheral Neuropathy, Blood Glucose, and Glycemic Control”, Diabetes Care, (1997);20:419-423. A related finding is that patients with Type 1 diabetes have low vagal tone in association with increased gastric antral size, possibly contributing to the dysmotility-associated symptoms seen in these patients. Undeland K A, et al., “Wide Gastric Antrum and Low Vagal Tone in Patients with Diabetes Mellitus Type 1 Compared to Patients with Functional Dyspepsia and Healthy Individuals”, Dig Dis Sci, (1996);41:9-16.
 The current treatments for gastroparesis are far from satisfactory. They include supportive care, such as dietary modification, prokinetic drugs, and; when required, interventions such as intravenous fluids and placement of a nasogastric tube may be needed.
 C. Gastroesophageal Reflux Disease (GERD)
 The fourth indication, GERD, can be associated with a wide spectrum of symptoms, including dyspepsia, reflux of gastric contents into the mouth, dysphagia, persistent cough, refractory hyperreactive airway disease and even chronic serous otitis media. Sontag SJ, et al., “Asthmatics with Gastroesophageal Reflux: Long Term Results of a Randomized Trial of Medical and Surgical Antireflux Therapies”, Am J Gastroenterol, (2003);98:987-999. Poelmans J, et al., “Prospective Study on the Incidence of Chronic Ear Complaints Related to Gastroesophageal Reflux and on the Outcome of Antireflux Therapy”, Ann Otol Rhinol Laryngol, (2002);111:933-938.
 GERD is considered to be a chronic condition for which long-term medical therapy and/or surgical therapy is often deemed necessary, in significant part because esophageal adenocarcinoma is sometimes a consequence of GERD. DeVault KR, et al., “Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease”, Am J Gastroenterol, (1999);94:1434-1442. Lagergren J, et al., “Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma”, New Engl J Med, (1999);340:825-831.
 The underlying pathophysiological mechanisms in GERD are considered to be transient lower esophageal relaxations (TLESRs) in the presence of either an inadequate pressure gradient between the stomach and the esophagus across the lower esophageal sphincter and/or low amplitude esophageal activity at times when gastric contents do reflux into the esophagus. In addition, gastric distention is thought to be associated with an increase in TLESRs. Mittal RK, et al., “Mechanism of Disease: The Esophagogastric Junction”, New Engl J Med, (1997);336:924-932. Scheffer RC, et al., “Elicitation of Transient Lower Oesophageal Sphincter Relaxations in Response to Gastric Distension”, Neurogastroenterol Motil, (2002);14:647-655.
 GERD is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the esophageal lumen to acidic gastric contents. Hunt, “The Relationship Between The Control Of pH And Healing And Symptom Relief In Gastro-Oesophageal Reflux Disease”, Ailment Pharmacol Ther., 9 (Suppl. 1) pp. 3-7 (1995). Many factors are believed to contribute to the onset of GERD. These include transient lower esophageal sphincter relaxations (as previously described), decreased LES resting tone, delayed stomach emptying and an ineffective esophageal clearance.
 Certain drugs have had some effectiveness at controlling GERD but fail to treat underlying causes of the disease. Examples of such drugs are H2-receptor antagonists (which control gastric acid secretion in the basal state) and proton pump inhibitors (which control meal-stimulated acid secretion). Hunt, id. Both classes of drugs can raise intragastric pH to or about 4 for varying durations. Hunt, supra.
 Surgery treatments are also employed for the treatment of GERD and include techniques for bulking the lower esophageal sphincter such as fundoplication and techniques described in U.S. Pat. No. 6,098,629 Johnson et al, Aug. 8, 2000. Other surgical techniques include placement of pacemakers for stimulating muscle contractions in the esophageal sphincter, the stomach muscles or in the pyloric valve. U.S. Pat. No. 6,104,955 to Bourgeois, U.S. Pat. No. 5,861,014 to Familoni.
 A summary of GERD treatments can be found in DeVault, et al., “Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease”, Amer. J. of Gastroenterology, Vol. 94, No. 6, pp. 1434-1442 (1999).
 Notwithstanding multiple attempts at various types of treatment, GERD continues to be a serious disease proving to be difficult to treat by any of the foregoing prior art techniques. In view of the foregoing and notwithstanding various efforts exemplified in the prior art, there remains a need for an effective treatment for GERD. It is an object of the present invention to provide a novel treatment and novel apparatus for the treatment of GERD.
 D. Electrical Stimulation to Treat GI Disorders
 Treatment of gastrointestinal diseases through nerve stimulation have been suggested. For example, U.S. Past. No. 6,238,423 to Bardy dated May 29, 2001 describes a constipation treatment involving electrical stimulation of the muscles or related nerves of the gut. U.S. Pat. No. 6,571,127 to Ben-Haim et al. dated May 27, 2003 describes increasing motility by applying an electrical field to the GI tract. U.S. Pat. No. 5,540,730 to Terry, Jr. et al., dated Jul. 30, 1996 describes a motility treatment involving vagal stimulation to alter GI contractions in response to a sense condition indicative of need for treatment. The '730 patent also uses a definition of dysmotility more restrictive than in the present application. In the '730 patent, dysmotility is described as hyper- or hypo-contractility. In the present application, dysmotility is a broader concept to refer to all abnormalities of gastric emptying or bowel transfer regardless of cause. U.S. Pat. No. 6,610,713 to Tracey dated Aug. 26, 2003 describes inhibiting release of a proinflammatory cytokine by treating a cell with a cholinergic agonist by stimulating efferent vagus nerve activity to inhibit the inflammatory cytokine cascade.
 A substantial body of literature is developed on nerve stimulation. For example, in Dapoigny et al., “Vagal influence on colonic motor activity in conscious nonhuman primates”, Am. J. Physiol., 262: G231-G236 (1992), vagal influence on colonic motor activity was investigated in conscious monkeys. To block antidromic interference, the vagus was blocked via vagal cooling and a vagal stimulation electrode was implanted distal to the vagal block. It was noted that vagal efferent stimulation increased contractile frequency and that the vagus has either a direct or indirect influence on fasting and fed colonic motor activity throughout the colon, and that a non-adrenergic, noncholinergic inhibitory pathway is under vagal control.
 Colonic and gastric stimulation are also described in a number of articles associated with M. P. Mintchev. These include: Mintchev, et al., “Electrogastrographic impact of multi-site functional gastric electrical stimulation”, J. of Medical Eng. & Tech., Vol. 23, No. 1 pp. 5-9 (1999); Rashev, et al., “Three-dimensional static parametric modeling of phasic colonic contractions for the purpose of microprocessor-controlled functional stimulation”, J. of Medical Eng. & Tech., Vol. 25, No. 3 pp. 85-96 (2001); Lin et al., “Hardware—software co-design of portable functional gastrointestinal stimulator system”, J. of Medical Eng. & Tech., Vol. 27, No. 4 pp. 164-177 (2003); Amaris et al., “Microprocessor controlled movement of solid colonic content using sequential neural electrical stimulation”, Gut, 50: pp 475-479 (2002) and Rashev et al., “Microprocessor-Controlled Colonic Peristalsis”, Digestive Diseases and Sciences, Vol. 47, No. 5, pp. 1034-1048 (2002).
 The foregoing references describe nerve stimulation to stimulate muscular contraction in the GI tract. As will be more fully discussed, the present invention utilizes vagal stimulation to improve vagal tone (similar in concept to improving cardiac electrical tone through cardiac pacing) and/or to treat GI disorders by altering the nature of duodenum contents by stimulation pancreatic and biliary output. The invention is also applicable to treating other diseases such as neuropsychiatric disorders.
 Vagal tone has been shown to be associated with dyspepsia. Hjelland, et al., “Vagal tone and meal-induced abdominal symptoms in healthy subjects”, Digestion, 65: 172-176 (2002). Also, Hausken, et al., “Low Vagal Tone and Antral Dysmotility in Patients with Functional Dyspepsia”, Psychosomatic Medicine, 55: 12-22 (1993). Also, decreased vagal tone has been associated with irritable bowel syndrome. Heitkemper, et al., “Evidence for Automatic Nervous System Imbalance in Women with Irritable Bowel Syndrome”, Digestive Diseases and Sciences, Vol. 43, No. 9, pp. 2093-2098 (1998).
 Also, as will be discussed, the present invention includes, in several embodiments, a blocking of a nerve (such as the vagal nerve) to avoid antidromic influences during stimulation. Cryogenic nerve blocking of the vagus is described in Dapoigny et al., “Vagal influence on colonic motor activity in conscious nonhuman primates”, Am. J. Physiol., 262: G231-G236 (1992). Electrically induced nerve blocking is described in Van Den Honert, et al., “Generation of Unidirectionally Propagated Action Potentials in a Peripheral Nerve by Brief Stimuli”, Science, Vol. 206, pp. 1311-1312. An electrical nerve block is described in Solomonow, et al., “Control of Muscle Contractile Force through Indirect High-Frequency Stimulation”, Am. J. of Physical Medicine, Vol. 62, No. 2, pp. 71-82 (1983) and Petrofsky, et al., “Impact of Recruitment Order on Electrode Design for Neural Prosthetics of Skeletal Muscle”, Am. J. of Physical Medicine, Vol. 60, No.5, pp. 243-253 (1981). A neural prosthesis with an electrical nerve block is also described in U.S. Patent Application Publication No. US 2002/0055779 A1 to Andrews published May 9, 2002. A cryogenic vagal block and resulting effect on gastric emptying are described in Paterson C A, et al., “Determinants of Occurrence and Volume of Transpyloric Flow During Gastric Emptying of Liquids in Dogs: Importance of Vagal Input”, Dig Dis Sci, (2000);45:1509-1516.
 According to a preferred embodiment of the present invention, a method and apparatus are disclosed for treating at least one of a plurality of gastrointestinal disorders of a patient characterized at least in part by an altered autonomic balance or altered motility. The method includes electrically stimulating an enteric nervous system of the patient to enhance a functional tone of the enteric nervous system.
 Enteric rhythm management (ERM) treats GI diseases in which dysmotility is thought to play a major role. This therapy is based on the physiological actions of pancreatic exocrine secretion and bile on the composition (osmolality and pH) and the digestion (enzymatic activity and, in the case of fats, emulsification) of intra-duodenal chyme, thereby presenting a novel approach to regulating the motility of the GI tract and, in particular, gastric emptying and the digestion and propulsion of chyme through the duodenum and into the jejunum and ileum.
 ERM as a therapy for GI diseases involving dysmotility is based on the following: (1) pacing the delivery of pancreatic exocrine secretion and bile can be used to either up- or down-regulate at least two aspects of GI motility—gastric emptying and small bowel transit—by modulating the osmolality, the pH and the digestion, including emulsification as needed, of intra-duodenal chyme; (2) pacing the efferent activity of the intra-abdominal vagus nerve as needed while blocking afferent activity of that same nerve as needed can be used to treat GI dysmotility in patients with either increased or decreased vagal tone as a component of their disease; and, (3) treating GI dysmotility disorders can and often does require flexibility in adjusting treatment algorithms based on symptomatic response because of inter-patient differences with a diagnostic group and because of intra-patient variability over time.
 The goals of enteric rhythm management in gastroparesis are: 1) to regulate the composition and digestion of duodenal chyme and, by so doing, to facilitate gastric emptying through the modulatory effect of duodenal chemo- and mechanoreceptors on the pylorus and 2) to up-regulate or down-regulate vagal tone to optimize gastricintestinal motility and symptom relief.
 In patient with GERD, ERM utilizing a physiologic enteric pacing device will, as described earlier, allow pacing of the delivery of pancreatic exocrine secretion and bile, thereby initiating pyloric relaxation, gastric emptying and consequent reduction in gastric distention, leading to a decrease in the underlying mechanism of GERD, that is, TLESRs.
 Kellow J E, et al., “Rome II: A Multinational Consensus Document on Gastrointestinal Disorders—Principles of Applied Neurogastroenterology: Physiology/Motility-Sensation”, Gut, (1999);45(Suppl II):II17-II24. Paterson C A, et al., “Determinants of Occurrence and Volume of Transpyloric Flow During Gastric Emptying of Liquids in Dogs: Importance of Vagal Input”, Dig Dis Sci, (2000);45:1509-1516. Tougas G, “The Autonomic Nervous System in Functional Bowel Disorders”, Gut, (2000);47(Suppl IV):iv78-iv80. Guyton A C, et al., “Propulsion and Mixing of Food in the Alimentary Tract”, Textbook of Medical Physiology, 10th ed. Philadelphia: W. B. Saunders and Company, 200:728-737. Guyton A C, et al., “Secretory Functions of the Alimentary Tract”, Textbook of Medical Physiology, 10th ed. Philadelphia: W. B. Saunders and Company, 200:738-753. Schwartz M P, et al., “Human Duodenal Motor Activity in Response to Acid and Different Nutrients”, Dig Dis Sci, (2001);46:1472-1481. Schwartz MP, et al., “Chemospecific Alterations in Duodenal Perception and Motor Response in Functional Dyspepsia”, Am J Gastroenterol, (2001);96:2596-2602.
 ERM involves pacing and thereby regulating the timing and the volume of pancreatic exocrine secretion and bile delivered to the intraluminal contents of the duodenum. In one embodiment, this is accomplished with a small, laparoscopically implantable and programmable medical device called a physiologic enteric pacing device. Three leads are positioned intra-abdominally and then connected to a subcutaneous, programmable pulse generator. A pacing lead may be placed on the anterior vagal trunk and another pacing lead may be placed on the posterior vagal trunk. One or more intra-abdominal electrode, i.e. blocking electrodes, may be placed on the vagus nerve proximal to the pacing leads.
 An additional embodiment of the present invention pertains to treating at least one of a plurality of gastrointestinal disorders of a patient by electrically stimulating a vagus nerve of the patient at a stimulation site proximal to at least one site of vagal innervation of a gastrointestinal organ. The electrical stimulation includes applying a stimulation signal at the stimulation site. A proximal electrical blocking signal is applied to the vagus nerve at a proximal blocking site proximal to the stimulation site. The proximal blocking signal is selected to at least partially block nerve impulses proximal to the proximal blocking site.
 The invention further includes a treatment apparatus having a stimulation electrode adapted for placement on a nerve of a patient at a stimulation site and a stimulation signal generator for generating a stimulation signal at the stimulation electrode and selected to electrically stimulate a nerve to induce bi-directional propagation of nervous impulses in a stimulated nerve. The apparatus includes a blocking member for placement on the nerve at a blocking site and creating localized conditions at the blocking site that at least partially diminish transmission of nerve impulses past the blocking site.
 A still further embodiment of the present invention includes a method for treating at least one of a plurality of disorders of a patient where the disorders are associated with a gastrointestinal tract of a patient where the disorders are characterized at least in part by hyper-tonal vagal activity innervating at least one of a plurality of alimentary tract organs of the patient at an innervation site. The method includes applying a neural conduction block to a vagus nerve of the patient at a blocking site proximal to the innervation site. The neural conduction block is selected to at least partially block nerve impulses on the vagus nerve distal to the blocking site.
 A yet further embodiment pertains to a treatment apparatus having an electrically controllable neural conduction electrode adapted to be placed on a vagus nerve of a patient at a blocking site proximal to an innervation site. A blocking signal generator generates a blocking signal selected to at least partially block nerve impulses on the vagus nerve distal to the blocking site.
 A still additional embodiment of the present invention includes a method for treating at least one of a plurality of disorders of a patient by electrically stimulating a vagus nerve at a stimulation site with a stimulation signal selected to have a therapeutic effect on a target organ. An electrical blocking signal is applied to the vagus nerve at a blocking site on a side of said stimulation site opposite the target organ. The blocking signal is selected to at least partially block nerve impulses to a second organ on a side of said blocking site opposite the stimulation site. In specific examples, the target organ may be gastrointestinal or central nervous with the other organ being cardio-respiratory.
FIG. 1 is a schematic representation of a gastric-emptying feedback loop with a patient-controlled stimulator for stimulating an organ of the loop;
FIG. 2 is a view similar to FIG. 1 with an automatic controller replacing the patient-controller of FIG. 1 and with feedback circuits to the automatic controller schematically represented;
FIG. 3 is a schematic illustration of an alimentary tract (GI tract plus non-GI organs such as the pancreas and liver) and its relation to vagal and enteric innervation;
FIG. 4 is the view of FIG. 3 showing the application of a pacing electrode according to an embodiment of the present invention;
FIG. 5 is a schematic representation of pacing system;
FIG. 6 is the view of FIG. 4 showing the application of a nerve conduction block electrode proximal to the pacing electrode;
FIG. 7 is the view of FIG. 6 showing the application of a nerve conduction block electrode distal to the pacing electrode; and
FIG. 8 is the view of FIG. 3 showing the application of a nerve conduction block electrode according to an embodiment of the present invention.
 With reference now to the various drawing figures in which identical elements are numbered identically throughout, a description of the preferred embodiment of the present invention will now be described.
 A. Invention of Parent Application
FIGS. 1 and 2 and the description which follow are from the aforementioned U.S. patent application Ser. No. 10/358,093 filed Feb. 3, 2003 filed Feb. 3, 2003 and entitled “Method and Apparatus for Treatment of Gastroesophageal Disease (GERD)”.
 With initial reference to FIG. 1, a gastric emptying feedback loop is shown schematically for ease of illustration. The feedback loop illustrates a patient's stomach S which is provided with food from the esophagus E. A lower esophageal sphincter LES is shown positioned between the esophagus E and the stomach S. The lower esophageal sphincter normally provides control of reflux of stomach contents into the esophagus E.
 On a proximal or lower end of the stomach S the stomach discharges into the superior duodenum D which is an upper portion of the intestines. The superior duodenum D and the stomach S are separated by a pyloric valve PV which opens to permit gastric emptying from the stomach into the duodenum D.
 Also schematically illustrated in FIG. 1 are nerve paths N providing signal flow paths from both the superior duodenum D and the stomach S to the brain B. An efferent Vagal nerve VN connects the brain B to the pancreas P of the patient. A conduit (pancreatic duct PD) extends from the pancreas P and discharges into the superior duodenum D.
 The presence of food contents within the duodenum D (such contents being referred to as “chyme”) may prevent passage of gastric content of the stomach S past the pyloric valve PV into the duodenum D. As long as such gastric contents cannot be passed into the duodenum D, such contents can be forced retrograde past the lower esophageal sphincter LES and into the esophagus E creating the symptoms and discomfort of GERD. The contents discharging from the stomach S into the duodenum D are acidic (and high osmolality) and reside in the duodenum D until pH is elevated (close to a neutral pH of 6-7) and osmolality is normalized.
 The elevation of pH and reduction of osmolality of chyme in the duodenum D results from exocrine secretion being administered from the pancreas P and from bile from the liver into the duodenum D. This raises the pH and lowers the osmolality of the duodenum D content permitting discharge from the duodenum D and thereby permitting gastric emptying across the pyloric valve PV.
 According to the present invention gastroesophageal reflux disease (GERD) results from a derangement of the feedback loops involved in upper GI digestion and motility control. This problem encompasses receptors and reflexes that regulate the propulsive contractions of the stomach, upper duodenum and biliary tree and the secretions of the exocrine pancreas. The interaction of these receptors and reflexes control gastric emptying (by coordinating gastric propulsive contractions and sphincter [primarily pyloric] tone) and regulate the pH and osmolality of the chyme in the duodenum. This chemo-regulation is mediated through control of bile delivery and stimulation of secretion by the exocrine pancreas of fluid delivered to the superior duodenum. Chey et al., “Neural Hormonal Regulation of Exocrine Pancreatic Secretion”, Pancreatology, pp. 320-335 (2001).
 Normally, ingestate delivered to the stomach is mixed by low intensity gastric mixing contractions with the enzymatic, ionic, including hydrogen ion (H+), and water secretions of the glands of the stomach. When the material is adequately reduced in size and is a smooth consistency, the fluid, now called chyme, is delivered to the ampulla of the small intestine by the much stronger propulsive, or emptying, contractions of the stomach coupled with transitory relaxation of the pyloric sphincter. This material is at a very low pH (about 2) and high osmolality, which activates receptors, including those for H+ and osmotic pressure, which are abundant in the wall of the ampulla. This receptor activation initiates the series of reflexes that cause pancreatic exocrine secretion to be delivered into the superior duodenum and ampulla. This fluid contains digestive enzymes, water and buffering compounds to raise the pH, and reduce the osmolality, of the chyme.
 Once a neutral pH and physiological osmolality are achieved, then propulsive contractions in the superior duodenum move the chyme out of the superior portion into the length of the duodenum; At which point the stretch and baro-receptors in the ampulla allow the pyloric sphincter to relax and another bolus of gastric contents is delivered into the ampulla by the peristaltic gastric emptying contractions. This material, at a very low pH (less than 2), activates hydrogen ion (H+) on receptors of the ampulla (upper most portion of the duodenum) causing the pancreatic fluids to be delivered to the material in the ampulla restarting the cycle as described above. Chapter 3, “The Stomach”, Gastrointestinal System, 2nd Ed., M. S. Long editor, Mosby Publisher, London (2002).
 If the control system is down regulated by, for example, by increased pH of gastric contents entering the ampulla, feedback may thereby be reduced from the H+ receptors in the duodenum that stimulate pancreatic exocrine secretion and bile delivery to the duodenum, then movement of chyme from the superior duodenum is delayed, causing delay of gastric emptying. Mabayo, et al., “Inhibition of Food Passage by Osmeprazole in the Chicken”, European J. of Pharmacology, pp. 161-165 (1995).
 In GERD, this reflex is inhibited in such a way that the stomach empties more slowly so that the gastric emptying contractions force gastric contents to flow retrograde into the esophagus. This is a result of the situation in which the gastric emptying contractions are vigorous but must operate against a contracted pyloric sphincter. These vigorous peristaltic contractions eventually begin to force gastric contents to flow retrograde into the esophagus because of the inherent imbalance between a very strong pyloric sphincter and a much weaker gastroesophageal sphincter. The delay in gastric emptying is directly related to a slow down in the transport of chyme out of the ampulla and superior duodenum. The drugs used to treat this disease raise pH further dampening the hydrogen-receptor-pancreatic secretion loop, further delaying gastric emptying. Benini, “Gastric Emptying and Dyspeptic Symptoms in Patients with Gastroesophageal Reflux”, Amer. J. of Gastroenterology, pp. 1351-1354 (1996).
 The present invention is directed towards reestablishing the link between gastric emptying and pancreatic secretion delivery, thereby addressing the main pathology of this disease by shortening chyme residence time in the superior duodenum so that intestinal contents move into the distal digestive tract in a more normal manner. According to a first embodiment, this is done by stimulating the H+ ion receptors or by stimulation of the pancreas directly or via its para-sympathetic innervation (pre-ganglionic Vagal nerves). Stimulation of pancreatic exocrine secretion has been shown by direct stimulation of the thoracic vagus nerves in dogs. Kaminski et al., “The Effect of Electrical Vagal Stimulation on Canine Pancreatic Exocrine Function”, Surgery, pp. 545-552 (1975). This results in a more rapid (normal) neutralization of chyme in the ampulla, allowing it move down the duodenum more quickly so that gastric emptying is returned to a more normal pace.
 Acidity (pH) can be assessed by measuring bicarbonate. It will be understood that references to —H includes such indirect measurements. Also, effects of the therapy described herein can be assessed and/or controlled by measuring an indication of pancreatic exocrine secretion or bile (e.g., HCO3 −).
 An alternative embodiment uses gastrocopic delivery of a paralyzing agent (e.g. botulism toxin) to the pyloric valve along with use of H2 antagonists or PPI's to manage the acidity of the chyme reaching the duodenum.
 As an additional alternative to pancreatic stimulation, the gall bladder can be stimulated to encourage bile movement into the duodenum. Shown schematically in the figures, the gall bladder GB resides below the liver L. The gall bladder is connected to the small intestine (specifically the duodenum D) via a bile duct BD. The bile duct BD can discharge directly into the duodenum D or via the pancreatic duct PD as shown. The bile can normalize the chyme to accelerate duodenal emptying. Bile consists of bile acids (detergents that emulsify lipids), cholesterol, phospholipids, electrolytes such as (Na+, K+, Ca+2, Cl−, HCO3 −) and H2O. Chapter 4, “The Liver and Biliary Tract”, Gastrointestinal System, 2nd Ed., M. S. Long editor, Mosby Publisher, London (2002). The gall bladder GB or bile duct can be stimulated indirectly via stimulation of the vagal nerve VN or directly stimulated by an electrode 11 (shown in phantom lines).
 As illustrated in the figures, an electrical stimulator 10, 20 which may be implanted is provided which alternatively may be directly connected to the Vagal nerve VN or the pancreas P to stimulate the pancreas directly or indirectly to excrete exocrine into the duodenum D (or more distally into the small intestine—e.g., into the jejunum) and increase the pH of chyme in the duodenum D as described. Alternatively, the same can be done to promote bile release. The frequency may be varied to maximize the response and selectively stimulate exocrine instead of endocrine secretions. Rosch et al., “Frequency-Dependent Secretion of Pancreatic Amylase, Lipase, Trypsin, and Chymotrypsin During Vagal Stimulation in Rats”, Pancreas, pp. 499-506 (1990). See, also, Berthoud et al., “Characteristics of Gastric and Pancreatic Reponses to Vagal Stimulation with Varied Frequencies: Evidence for Different Fiber Calibers?”, J. Auto. Nervous Sys., pp. 77-84 (1987) (showed frequency-response relationship with insulin, i.e., significantly less insulin was released at lower frequencies −2 Hz v. 8 Hz—also, frequency-response curves evidenced distinctly different profiles for gastric, pancreatic and cardiovascular responses.) Slight insulin release can maximize pancreatic exocrine secretion. Chey et al., “Neural Hormonal Regulation of Exocrine Pancreatic Secretion”, Pancreatology, pp. 320-335 (2001).
 With a patient control stimulation as shown in FIG. 1, the patient may activate the stimulator 10 by remote transmitter to stimulate an electrical charge either after eating (e.g., about 60 to 90 minutes after eating) or on onset of GERD symptoms. It will be appreciated that there are a wide variety of nerve stimulators and organ stimulators available for implantation and are commercially available and which include connectors for connecting directly to nerves.
FIG. 2 illustrates an additional embodiment where the patient activated loop is replaced with an automatic loop having a programmable stimulator 20 which receives as an input signals from sensors in the duodenum to measure pH, osmolality or strain (e.g., from baro-sensors) on the duodenum indicating filling or may measure acidity in the esophagus or strain on the lower esophageal sphincter LES or stomach S all of which may be provided to the implantable controller 20 which can be provided with desirable software to process the incoming signals and generate a stimulating signal to either the vagal nerve, the pancreas P or the duodenum D (or jejunum) directly in response to such received signals. It will be appreciated that stimulators and controllers are well within the skill of the art. U.S. Pat. No. 5,540,730 teaches a neurostimulator to stimulate a vagus nerve to treat a motility disorder. U.S. Pat. No. 5,292,344 teaches gastrointestinal sensors, including pH sensors.
 B. Application of Parent Application to Treatments Other than GERD
 In addition to treatment of GERD, the foregoing invention is applicable to treatment of a plurality of GI diseases associated with delayed gastric emptying or altered autonomic activity. These include functional gastrointestinal disorders and gastroparesis. Furthermore, applicants have determined that duodenal content impacts a plurality of motility disorders throughout the bowels and can diseases associated with dysmotility (e.g., irritable bowel syndrome). Accordingly it is an object of the present invention to use the teachings of the aforementioned parent application to treat GI disorders associated with delayed gastric emptying and abnormal intestinal transport.
 C. Additional Disclosure of the Present Application
 1. Enteric Innervation
FIG. 3 is a schematic illustration of an alimentary tract (GI tract plus non-GI organs such as the pancreas and ball bladder, collectively labeled PG) and its relation to vagal and enteric innervation. The lower esophageal sphincter (LES) acts as a gate to pass food into the stomach S and, assuming adequate function of all components, prevent reflux. The pylorus PV controls passage of chyme from the stomach S into the intestines I (collectively shown in the figures and including the large intestine or colon and the small intestine including the duodenum, jejunum and ileum).
 The biochemistry of the contents of the intestines I is influenced by the pancreas P and gall bladder PG which discharge into the duodenum. This discharge is illustrated by dotted arrow A.
 The vagus nerve VN transmits signals to the stomach S, pylorus PV, pancreas and gall bladder PG directly. Originating in the brain, there is a common vagus nerve VN in the region of the diaphragm (not shown). In the region of the diaphragm, the vagus VN separates into anterior and posterior components with both acting to innervate the GI tract. In FIGS. 3, 5-8, the anterior and posterior vagus nerves are not shown separately. Instead, the vagus nerve VN is shown schematically to include both anterior and posterior nerves.
 The vagus nerve VN contains both afferent and efferent components sending signals away from and to, respectively, its innervated organs.
 In addition to influence from the vagus nerve VN, the GI and alimentary tracts are greatly influenced by the enteric nervous system ENS. The enteric nervous system ENS is an interconnected network of nerves, receptors and actuators throughout the GI tract. There are many millions of nerve endings of the enteric nervous system ENS in the tissues of the GI organs. For ease of illustration, the enteric nervous system ENS is illustrated as a line enveloping the organs innervated by the enteric nervous system ENS
 The vagus nerve VN innervates, at least in part, the enteric nervous system ENS (schematically illustrated by vagal trunk VN3 which represents many vagus-ENS innervation throughout the cut). Also, receptors in the intestines I connect to the enteric nervous system ENS. Arrow B in the figures illustrates the influence of duodenal contents on the enteric nervous system ENS as a feedback to the secretion function of the pancreas, liver and gall bladder. Specifically, receptors in the intestine I respond the biochemistry of the intestine contents (which are chemically modulated by the pancreao-biliary output of Arrow A). This biochemistry includes pH and osmolality.
 In the figures, vagal trunks VN1, VN2, VN4 and VN6 illustrate schematically the direct vagal innervation of the GI organs of the LES, stomach S, pylorus PV and intestines I. Trunk VN3 illustrates direct communication between the vagus VN and the ENS. Trunk VN5 illustrates direct vagal innervation of the pancreas and gall bladder. Enteric nerves ENS1-ENS4 represent the multitude of enteric nerves in the stomach S, pylorus PV, pancreas and gall bladder PG and intestines I.
 While communicating with the vagus nerve VN, the enteric nervous system ENS can act independently of the vagus and the central nervous system. For example, in patients with a severed vagus nerve (vagotomy—an historical procedure for treating ulcers), the enteric nervous system can operate the gut. Most enteric nerve cells are not directly innervated by the vagus. Gershon, “The Second Brain”, Harper Collins Publishers, Inc, New York, N.Y. p. 19 (1998)
 In FIG. 3, the vagus VN and its trunks (illustrated as VN1-VN6) and the enteric nervous system ENS are shown in phantom lines to illustrate reduced vagal and enteric nerve tone (i.e., sub-optimal nerve transmission levels). Reduced vagal and enteric tone contribute directly to the ineffectiveness of the GI organs as well as indirectly (through reduced pancreatic/biliary output). The reduced pancreatic/biliary output is illustrated by the dotted presentation of arrow A. As previously discussed, the vagus can be stimulated to stimulate pancreatic or biliary output. Therefore, the reduced output of arrow A results in a reduced feedback illustrated by the dotted presentation of arrow B.
 2. Enteric Rhythm Management (ERM)
 The benefits of the present invention are illustrated in FIG. 4 where a stimulating or pacing electrode PE is applied to the vagus VN. While only one electrode is shown in FIG. 4, separate electrodes could be applied to both the anterior and posterior vagus nerves (or to the common vagus or vagal branches). In a preferred embodiment, the electrode PE is placed a few centimeters below the diaphragm and proximal to stomach and pancreo/biliary innervation. While this placement is presently preferred for ease of surgical access, other placement locations may be used.
 By pacing the vagus through the pacing electrode, vagal tone is optimized by either up- or down-regulation. With reference to the parasympathetic and enteric nervous systems, “tone” refers to basal activity of a nerve or nervous system facilitating appropriate physiologic response to a patient's internal environment. For example, low vagal tone implies a reduction in vagus nerve activity resulting in decreased response of the alimentary tract to ingested food. As used in the present application, “pacing” is not limited to mean timed events coordinated with specifically timed physiologic events. Instead, pacing means any electrical stimulation of a nerve trunk to induce bi-directional propagation of nervous impulses in the stimulated nerve.
 The operating effectiveness of the vagus is enhanced so that local physiological signals generated in the enteric nervous system (or sent to the brain from the organs) are more appropriately responded to within the alimentary tract. Due to its innervation of the enteric nervous system, pacing of the vagus enhances the functional tone of the enteric nervous system. By enhancing the functional tone it will be noted that the stimulation pacing is elevating the degree of functionality of the vagus and enteric nerves. In this context, “pacing” is not meant to mean timed pulsed coordinated with muscular contractions or synchronized with other invents. Pacing means elevating the activity level of the nerves.
 Tonal enhancement of the vagus and enteric nerves is illustrated by the solid lines for the nerves VN, ENS in FIG. 4. Vagal trunk VN5 is in solid line to illustrate enhanced tone of the many vagal nerve components communicating with the enteric nervous system ENS. Direct vagal innervation of the LES, stomach S, pylorus PV and intestines I remains shown as low tone indicated by phantom lines VN1, VN2, VN4, VN6. The tonal pacing described herein is not intended to trigger or drive the muscular contractility of these organs. The stimulation is not intended to be timed to trigger contractility and is not provided with an energy level sufficient to drive peristaltic contractions. Instead, these functions remain controlled by the central and enteric nerves systems. The enhanced nerve tone provided by the present invention permits these functions to occur.
 Pacing to enhance vagal tone is not initiated in response to any senses event (or in anticipation of an immediate need to GI activity). Instead, the pacing can be done intermittently over the day to provide an enhanced level of operating functionality to the vagus. By way of non-limiting example, the stimulation pacing can be done during awake hours. For example, every ten minutes, pacing signals can be sent to the pacing electrodes. The pacing signals have a duration of 30 seconds with a current of 4 mA, a frequency of 12 Hz and an impulse duration of 2 msec. These parameters are representative only. A wide range of signal parameters may be used to stimulate the vagus nerve. Examples of these are recited in the afore-referenced literature
 As will be further discussed, the present invention permits ERM to be uniquely designed and modified by an attending physician to meet the specific needs of individual patients. For example, pacing can be limited to discrete intervals in the morning, afternoon and evening with the patient free to coordinate meals around these events.
 In addition to enhancing vagal and enteric tone directly, the pacing also enhances the pancreatic and biliary output for the reasons discussed above. Namely, while ERM does not drive muscular events over nerve trunks VN1, VN2, VN4, VN6, the enhanced tone stimulates pancreo-biliary output over trunk VN5 (illustrated by the solid line of VN5 in FIG. 4). This enhanced output is illustrated as solid arrow A′ in FIG. 4. As a consequence there is a greater feedback to the intestinal receptors as illustrated by solid arrow B′ in FIG. 4. This enhanced biochemistry feedback further enhances the tone of the enteric nervous system ENS.
 3. Implantable Pacing Circuit
 A representative pacing circuit 100 is schematically shown in FIG. 5. Similar to cardiac pacing devices, an implantable controller 102 contains an induction coil 104 for inductive electrical coupling to a coil 106 of an external controller 108. The implantable controller 102 includes anterior and posterior pulse generators 110, 112 electrically connected through conductors 114, 116 to anterior and posterior pacing electrodes 118, 120 for attachment to anterior and posterior trunks, respectively, of the vagus nerve VN. The implantable controller 102 also includes a battery 122 and a CPU 124 which includes program storage and memory. The timing and parameters of the pulse at the electrodes 118, 120 can be adjusted by inductively coupling the external controller 108 to the implantable controller 102 and inputting pacing parameters (e.g., pulse width, frequency and amplitude).
 While a fully implantable controller 102 is desirable, it is not necessary. For example, the electrodes 118, 120 can be implanted connected to a receiving antenna placed near the body surface. The control circuits (i.e., the elements 124, 110, 112 and 108) can be housed in an external pack worn by the patient with a transmitting antenna held in place on the skin over the area of the implanted receiving antenna. Such a design is forward-compatible in that the implanted electrodes can be later substituted with the implantable controller 102 at a later surgery if desired.
 Although not shown in FIG. 5, the controller 102 can also include circuits generating nerve conduction block signals (as will be described) which connect to electrodes which may be positioned on a nerve proximally, distally (or both) of the electrodes 118, 120.
 4. Nerve Conduction Block
FIG. 6 shows an alternative embodiment using a nerve conduction blocking electrode PBE proximal to the pacing electrode for providing a conduction block. A nerve block is, functionally speaking, a reversible vagotomy. Namely, application of the block at least partially prevents nerve transmission across the site of the block. Removal of the block restores normal nerve activity at the site. A block is any localized imposition of conditions that at least partially diminish transmission of impulses.
 The vagal block may be desirable in some patients since unblocked pacing may result in afferent vagal and antidromic efferent signals having undesired effect on organs innervated by the vagus proximal to the GI tract (e.g., undesirable cardiac response). Further, the afferent signals of the pacing electrode PE can result in a central nervous system response that tends to offset the benefits of the pacing electrode on the ENS and pancreo/biliary function, thereby reducing the GI and enteric rhythm management effectiveness of vagal pacing.
 The block may be intermittent and applied only when the vagus is paced by the pacing electrode PE. The preferred nerve conduction block is an electronic block created by a signal at the vagus by an electrode PBE controlled by the implantable controller (such as controller 102 or an external controller). The nerve conduction block can be any reversible block. For example, cryogenics (either chemically or electronically induced) or drug blocks can be used. An electronic cryogenic block may be a Peltier solid-state device which cools in response to a current and may be electrically controlled to regulate cooling. Drug blocks may include a pump-controlled subcutaneous drug delivery.
 With such an electrode conduction block, the block parameters (signal type and timing) can be altered by a controller and can be coordinated with the pacing signals to block only during pacing. A representative blocking signal is a 500 Hz signal with other parameters (e.g., timing and current) matched to be the same as the pacing signal). While an alternating current blocking signal is described, a direct current (e.g., −70 mV DC) could be used. The foregoing specific examples of blocking signals are representative only. Other examples and ranges of blocking signals are described in the aforementioned literature (all incorporated herein by reference). As will be more fully described, the present invention gives a physician great latitude in selected pacing and blocking parameters for individual patients.
 Similar to FIG. 4, the vagus VN and enteric nervous system ENS in FIG. 6 distal to the block PBE are shown in solid lines to illustrate enhanced tone (except for the direct innervation VN1, VN2, VN4, VN6 to the GI tract organs). Similarly, arrows A′, B′ are shown in solid lines to illustrate the enhanced pancreo-biliary output and resultant enhanced feedback stimulation to the enteric nervous system ENS. The proximal vagus nerve segment VNP proximal to the block PBE is shown in phantom lines to illustrate it is not stimulated by the pacing electrode PE while the blocking electrode PBE is activated.
 5. Proximal and Distal Blocking
FIG. 7 illustrates the addition over FIG. 6 of a nerve conductive block DBE distal to the pacing electrode PE. The proximal block PBE prevents adverse events resulting from afferent signals and heightens the GI effectiveness by blocking antidromic interference as discussed with reference to FIG. 6.
 In FIG. 7, the distal block DBE is provided in the event there is a desire to isolate the pacing effect of electrode PE. For example, a physician may which to enhance the vagus and enteric activity in the region proximal to the duodenum but may wish to avoid stimulating pancreo-biliary output. For example, a patient may have a GI problem without apparent colon dysfunction (e.g., gastroparesis functional dyspepsia without bowel symptoms). Placing the distal block DBE on a branch of the vagus between the pacing electrode PE and the pancreas and gall bladder PG prevents increased pancreo-biliary output and resultant feedback (illustrated by dotted arrows A and B in FIG. 7 and dotted distal vagal nerve segment VND and vagal trunk VN5).
 6. Blocking as an Independent Therapy
FIG. 8 illustrates an alternative embodiment of the invention.
 In certain patients, the vagus nerve may be hyperactive contributing to diarrhea-dominant IBS. Use of a blocking electrode alone in the vagus permits down-regulating the vagus nerve VN, the enteric nervous system ENS and pancreo-biliary output. The block down-regulates efferent signal transmission. In FIG. 8, the hyperactive vagus is illustrated by the solid line of the proximal vagus nerve segment VNP. The remainder of the vagus and enteric nervous system are shown in reduced thickness to illustrate down-regulation of tone. The pancreo-biliary output (and resulting feedback) is also reduced. In FIG. 8, the blocking electrode BE is shown high on the vagus relative to the GI tract innervation (e.g., just below the diaphragm), the sole blocking electrode could be placed lower (e.g., just proximal to pancreo/biliary innervation VN5).
 7. Application to Obesity
 The foregoing discussion has been described in a preferred embodiment of treating FGIDs, gastroparesis and GERD. Obesity is also treatable with the present invention.
 Recent literature describes potential obesity treatments relative to gut hormone fragment peptide YY3-36. See, e.g., Batterham, et al., “Inhibition of Food Intake in Obese Subjects by Peptide YY3-36”, New England J. Med., pp. 941-948 (Sep. 4, 2003) and Komer et al., “To Eat or Not to Eat—How the Gut Talks to the Brain”, New England J. Med., pp. 926-928 (Sep. 4, 2003). The peptide YY3-36 (PPY) has the effect of inhibiting gut motility through the phenomena of the ileal brake. Vagal afferents create a sensation of satiety.
 The present invention can electrically simulate the effects of PPY by using the vagal block to down-regulate afferent vagal activity to create a desired sensation of satiety. Since the down-regulation does not require continuous blocking signals, the beneficial efferent signals are permitted.
 8. Application to Other Therapies
 There are numerous suggestions for vagal pacing or stimulation to treat a wide variety of diseases. For example, U.S. Pat. No. 5,188,104 dated Feb. 23, 1993 describes vagal stimulation to treat eating disorders. U.S. Pat. No. 5,231,988 dated Aug. 3, 1993 describes vagal stimulation to treat endocrine disorders. U.S. Pat. No. 5,215,086 dated Jun. 1, 1993 describes vagal stimulation to treat migraines. U.S. Pat. No. 5,269,303 dated Dec. 14, 1993 describes vagal stimulation to treat dementia. U.S. Pat. No. 5,330,515 dated Jul. 19, 1994 describes vagal stimulation to treat pain. U.S. Pat. No. 5,299,569 dated Apr. 5, 1994 describes vagal stimulation to treat neuropsychiatric disorders. U.S. Pat. No. 5,335,657 dated Aug. 9, 1994 describes vagal stimulation to treat sleep disorders. U.S. Pat. No. 5,707,400 dated Jan. 13, 1998 describes vagal stimulation to treat refractory hypertension. U.S. Pat. No. 6,473,644 dated Oct. 29, 2002 describes vagal stimulation to treat heart failure. U.S. Pat. No. 5,571,150 dated Nov. 5, 1996 describes vagal stimulation to treat patients in comas. As previously described, U.S. Pat. No. 5,540,730 dated Jul. 30, 1996 describes vagal stimulation to treat motility disorders and U.S. Pat. No. 6,610,713 dated Aug. 26, 2003 describes vagal stimulation to inhibit inflammatory cytokine production. All of the foregoing U.S. patents listed in this paragraph are incorporated herein by reference.
 All of the foregoing suffer from undesired effects of vagal pacing on cardiovascular, gastrointestinal or other organs. Nerve conduction blocking permits longer pulse durations which would otherwise have adverse effects on other organs such as those of the cardiovascular or gastrointestinal systems. In accordance with the present invention, all of the foregoing disclosures can be modified by applying a blocking electrode and blocking signal as disclosed herein to prevent adverse side effects. By way of specific example, pacing a vagus nerve in the thoracic cavity or neck combined with a blocking electrode on the vagus nerve distal to the pacing electrode can be used to treat neuropsychiatric disorders (such as depression and schizophrenia) and Parkinson's and epilepsy and dementia. In such treatments, the blocking electrode is placed distal to the stimulating electrode 25 shown in FIGS. 4 and 2, respectively, of each of U.S. Pat. Nos. 5,269,303 and 5,299,569. The present invention thereby enables the teachings of the afore-referenced patents listed in foregoing two paragraphs.
 As described, the parameters of the stimulating and blocking electrodes can be inputted via a controller and, thereby, modified by a physician. Also, FIG. 2 illustrates a feedback for controlling a stimulating electrode. Feedbacks for stimulating electrodes are also described in the patents incorporated by reference. The blocking electrode can also be controlled by an implanted controller and feedback system. For example, physiologic parameters (e.g., heart rate, blood pressure, etc.) can be monitored. The blocking signal can be regulated by the controller to maintain measured parameters in a desired range. For example, blocking can be increased to maintain heart rate within a desired rate range during stimulation pacing.
 9. Opportunity for Physician to Alter Treatment for Specific Patient
 Gastrointestinal disorders are complex. For many, the precise mechanism is of the disorder is unknown. Diagnosis and treatment are often iterative processes. The present invention is particularly desirable for treating such disorders.
 Use of proximal and distal blocking electrodes in combination with one or more pacing electrode permits a physician to alter an operating permutation of the electrodes. This permits regional and local up- or down-regulation of the nervous system and organs. Further, pacing parameters (duty cycle, current, frequency, pulse length) can all be adjusted. Therefore, the treating physician has numerous options to alter a treatment to meet the needs of a specific patient.
 In addition, a physician can combine the present invention with other therapies (such as drug therapies like prokinetic agents).
 With the foregoing detailed description of the present invention, it has been shown how the objects of the invention have been attained in a preferred manner. Modifications and equivalents of disclosed concepts such as those which might readily occur to one skilled in the art, are intended to be included in the scope of the claims which are appended hereto.
|US5188104 *||1. Febr. 1991||23. Febr. 1993||Cyberonics, Inc.||Treatment of eating disorders by nerve stimulation|
|US5199430 *||11. März 1991||6. Apr. 1993||Case Western Reserve University||Micturitional assist device|
|US5215086 *||3. Mai 1991||1. Juni 1993||Cyberonics, Inc.||Therapeutic treatment of migraine symptoms by stimulation|
|US5231988 *||9. Aug. 1991||3. Aug. 1993||Cyberonics, Inc.||Treatment of endocrine disorders by nerve stimulation|
|US5263480 *||7. Aug. 1992||23. Nov. 1993||Cyberonics, Inc.||Treatment of eating disorders by nerve stimulation|
|US5269303 *||22. Febr. 1991||14. Dez. 1993||Cyberonics, Inc.||Treatment of dementia by nerve stimulation|
|US5292344 *||10. Juli 1992||8. März 1994||Douglas Donald D||Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port|
|US5299569 *||3. Mai 1991||5. Apr. 1994||Cyberonics, Inc.||Treatment of neuropsychiatric disorders by nerve stimulation|
|US5330515 *||17. Juni 1992||19. Juli 1994||Cyberonics, Inc.||Treatment of pain by vagal afferent stimulation|
|US5335657 *||3. Mai 1991||9. Aug. 1994||Cyberonics, Inc.||Therapeutic treatment of sleep disorder by nerve stimulation|
|US5423872 *||26. Mai 1993||13. Juni 1995||Cigaina; Valerio||Process and device for treating obesity and syndromes related to motor disorders of the stomach of a patient|
|US5514175 *||9. Nov. 1994||7. Mai 1996||Cerebral Stimulation, Inc.||Auricular electrical stimulator|
|US5540730 *||6. Juni 1995||30. Juli 1996||Cyberonics, Inc.||Treatment of motility disorders by nerve stimulation|
|US5571150 *||19. Dez. 1994||5. Nov. 1996||Cyberonics, Inc.||Treatment of patients in coma by nerve stimulation|
|US5690691 *||8. Mai 1996||25. Nov. 1997||The Center For Innovative Technology||Gastro-intestinal pacemaker having phased multi-point stimulation|
|US5707400 *||19. Sept. 1995||13. Jan. 1998||Cyberonics, Inc.||Treating refractory hypertension by nerve stimulation|
|US5716385 *||12. Nov. 1996||10. Febr. 1998||University Of Virginia||Crural diaphragm pacemaker and method for treating esophageal reflux disease|
|US5747060 *||26. März 1996||5. Mai 1998||Euro-Celtique, S.A.||Prolonged local anesthesia with colchicine|
|US5836994 *||30. Apr. 1997||17. Nov. 1998||Medtronic, Inc.||Method and apparatus for electrical stimulation of the gastrointestinal tract|
|US5861014 *||30. Apr. 1997||19. Jan. 1999||Medtronic, Inc.||Method and apparatus for sensing a stimulating gastrointestinal tract on-demand|
|US5919216 *||16. Juni 1997||6. Juli 1999||Medtronic, Inc.||System and method for enhancement of glucose production by stimulation of pancreatic beta cells|
|US5995872 *||1. Okt. 1998||30. Nov. 1999||Medtronic, Inc.||Method and apparatus for electrical stimulation of the gastrointestinal tract|
|US6083249 *||24. Sept. 1998||4. Juli 2000||Medtronic, Inc.||Apparatus for sensing and stimulating gastrointestinal tract on-demand|
|US6091992 *||15. Dez. 1997||18. Juli 2000||Medtronic, Inc.||Method and apparatus for electrical stimulation of the gastrointestinal tract|
|US6093167 *||16. Juni 1997||25. Juli 2000||Medtronic, Inc.||System for pancreatic stimulation and glucose measurement|
|US6097984 *||25. Nov. 1998||1. Aug. 2000||Medtronic, Inc.||System and method of stimulation for treating gastro-esophageal reflux disease|
|US6098629 *||7. Apr. 1999||8. Aug. 2000||Endonetics, Inc.||Submucosal esophageal bulking device|
|US6104955 *||15. Dez. 1997||15. Aug. 2000||Medtronic, Inc.||Method and apparatus for electrical stimulation of the gastrointestinal tract|
|US6135978 *||22. März 1999||24. Okt. 2000||Medtronic, Inc.||System for pancreatic stimulation and glucose measurement|
|US6216039 *||2. Mai 1997||10. Apr. 2001||Medtronic Inc.||Method and apparatus for treating irregular gastric rhythms|
|US6238423 *||30. Sept. 1999||29. Mai 2001||Medtronic, Inc.||Apparatus and method for treating chronic constipation|
|US6243607 *||4. Sept. 1997||5. Juni 2001||University Technologies International Inc.||Gastro-intestinal electrical pacemaker|
|US6261280 *||17. Apr. 2000||17. Juli 2001||Medtronic, Inc||Method of obtaining a measure of blood glucose|
|US6341236 *||30. Apr. 1999||22. Jan. 2002||Ivan Osorio||Vagal nerve stimulation techniques for treatment of epileptic seizures|
|US6364899 *||9. Juni 1999||2. Apr. 2002||Innercool Therapies, Inc.||Heat pipe nerve cooler|
|US6369079 *||29. Febr. 2000||9. Apr. 2002||Sepracor, Inc.||Methods for treating irritable bowel syndrome using optically pure (+) norcisapride|
|US6405732 *||1. Okt. 1999||18. Juni 2002||Curon Medical, Inc.||Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors|
|US6449511 *||14. Apr. 2000||10. Sept. 2002||University Technologies International Inc.||Gastrointestinal electrical stimulator having a variable electrical stimulus|
|US6473644 *||13. Okt. 1999||29. Okt. 2002||Cyberonics, Inc.||Method to enhance cardiac capillary growth in heart failure patients|
|US6558708 *||10. Apr. 2000||6. Mai 2003||Cedars-Sinai Medical Center||Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia|
|US6571127 *||11. Jan. 2000||27. Mai 2003||Impulse Dynamics N.V.||Method of increasing the motility of a GI tract|
|US6610713 *||15. Mai 2001||26. Aug. 2003||North Shore - Long Island Jewish Research Institute||Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation|
|US6684105 *||31. Aug. 2001||27. Jan. 2004||Biocontrol Medical, Ltd.||Treatment of disorders by unidirectional nerve stimulation|
|US6746474 *||31. Mai 2002||8. Juni 2004||Vahid Saadat||Apparatus and methods for cooling a region within the body|
|US6826428 *||11. Okt. 2000||30. Nov. 2004||The Board Of Regents Of The University Of Texas System||Gastrointestinal electrical stimulation|
|US6853862 *||28. März 2000||8. Febr. 2005||Medtronic, Inc.||Gastroelectric stimulation for influencing pancreatic secretions|
|US6895278 *||17. Dez. 1999||17. Mai 2005||Transneuronix, Inc.||Gastric stimulator apparatus and method for use|
|US6928320 *||17. Mai 2001||9. Aug. 2005||Medtronic, Inc.||Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated|
|US6993391 *||28. Mai 2003||31. Jan. 2006||Metacure N.V.||Acute and chronic electrical signal therapy for obesity|
|US7076307 *||8. Mai 2004||11. Juli 2006||Boveja Birinder R||Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders|
|US7167750 *||6. Jan. 2004||23. Jan. 2007||Enteromedics, Inc.||Obesity treatment with electrically induced vagal down regulation|
|US20020055779 *||5. März 1997||9. Mai 2002||Brian J. Andrews||Neural prosthesis|
|US20020161360 *||5. Febr. 2002||31. Okt. 2002||Carroll Ronald J.||Method and device for neurocryo analgesia and anesthesia|
|US20030018367 *||19. Juli 2002||23. Jan. 2003||Dilorenzo Daniel John||Method and apparatus for neuromodulation and phsyiologic modulation for the treatment of metabolic and neuropsychiatric disease|
|US20030045909 *||24. Juli 2002||6. März 2003||Biocontrol Medical Ltd.||Selective nerve fiber stimulation for treating heart conditions|
|US20030181958 *||13. Sept. 2002||25. Sept. 2003||Dobak John D.||Electric modulation of sympathetic nervous system|
|US20030181959 *||16. Okt. 2002||25. Sept. 2003||Dobak John D.||Wireless electric modulation of sympathetic nervous system|
|US20030212440 *||16. Juli 2002||13. Nov. 2003||Boveja Birinder R.||Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system|
|US20040039425 *||29. Mai 2003||26. Febr. 2004||Beverley Greenwood-Van Meerveld||Spinal cord stimulation as treatment for functional bowel disorders|
|US20040127953 *||20. Febr. 2002||1. Juli 2004||Kilgore Kevin L.||Systems and methods for reversibly blocking nerve activity|
|US20040167583 *||6. Jan. 2004||26. Aug. 2004||Enteromedics, Inc.||Electrode band apparatus and method|
|US20040172085 *||29. Sept. 2003||2. Sept. 2004||Beta Medical, Inc.||Nerve stimulation and conduction block therapy|
|US20040236381 *||19. Mai 2003||25. Nov. 2004||Medtronic, Inc.||Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof|
|US20040236382 *||19. Mai 2003||25. Nov. 2004||Medtronic, Inc.||Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof|
|US20040249416 *||12. Sept. 2003||9. Dez. 2004||Yun Anthony Joonkyoo||Treatment of conditions through electrical modulation of the autonomic nervous system|
|US20050038484 *||30. Juni 2004||17. Febr. 2005||Enteromedics, Inc.||Controlled vagal blockage therapy|
|US20050049655 *||27. Aug. 2003||3. März 2005||Boveja Birinder R.||System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities|
|US20050070970 *||12. Jan. 2004||31. März 2005||Knudson Mark B.||Movement disorder stimulation with neural block|
|US20050070974 *||12. Jan. 2004||31. März 2005||Knudson Mark B.||Obesity and eating disorder stimulation treatment with neural block|
|US20050137644 *||8. Jan. 2005||23. Juni 2005||Boveja Birinder R.||Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders|
|US20050143378 *||29. Dez. 2003||30. Juni 2005||Yun Anthony J.||Treatment of conditions through pharmacological modulation of the autonomic nervous system|
|US20050143787 *||13. Jan. 2005||30. Juni 2005||Boveja Birinder R.||Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator|
|US20050149141 *||30. Jan. 2004||7. Juli 2005||Starkebaum Warren L.||Gastric stimulation for altered perception to treat obesity|
|US20050149146 *||31. Jan. 2005||7. Juli 2005||Boveja Birinder R.||Method and system to provide therapy for obesity and other medical disorders, by providing electrical pules to symapthetic nerves or vagal nerve(s) with rechargeable implanted pulse generator|
|US20050149148 *||10. Febr. 2005||7. Juli 2005||Medtronic, Inc.||Apparatus and method for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated|
|US20060036293 *||29. Juli 2005||16. Febr. 2006||Whitehurst Todd K||Methods for treating gastrointestinal disorders|
|Zitiert von Patent||Eingetragen||Veröffentlichungsdatum||Antragsteller||Titel|
|US7054690||22. Okt. 2003||30. Mai 2006||Intrapace, Inc.||Gastrointestinal stimulation device|
|US7167750||6. Jan. 2004||23. Jan. 2007||Enteromedics, Inc.||Obesity treatment with electrically induced vagal down regulation|
|US7299091||1. Juli 2003||20. Nov. 2007||Cyberonics, Inc.||Treatment of obesity by bilateral vagus nerve stimulation|
|US7310557||29. Apr. 2005||18. Dez. 2007||Maschino Steven E||Identification of electrodes for nerve stimulation in the treatment of eating disorders|
|US7340306||18. Aug. 2003||4. März 2008||Cyberonics, Inc.||Treatment of obesity by sub-diaphragmatic nerve stimulation|
|US7430450||16. Nov. 2005||30. Sept. 2008||Intrapace, Inc.||Device and method for treating obesity|
|US7444183||6. Jan. 2004||28. Okt. 2008||Enteromedics, Inc.||Intraluminal electrode apparatus and method|
|US7657310||26. Jan. 2006||2. Febr. 2010||Cyberonics, Inc.||Treatment of reproductive endocrine disorders by vagus nerve stimulation|
|US7672727||17. Aug. 2005||2. März 2010||Enteromedics Inc.||Neural electrode treatment|
|US7676270||16. Nov. 2005||9. März 2010||Intrapace, Inc.||Radially expandable gastrointestinal stimulation device|
|US7689284||12. Okt. 2005||30. März 2010||Intrapace, Inc.||Pseudounipolar lead for stimulating a digestive organ|
|US7693577||22. Jan. 2007||6. Apr. 2010||Enteromedics Inc.||Irritable bowel syndrome treatment|
|US7702394||23. Sept. 2004||20. Apr. 2010||Intrapace, Inc.||Responsive gastric stimulator|
|US7705016||12. Febr. 2004||27. Apr. 2010||Albert Einstein College Of Medicine Of Yeshiva University||Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus|
|US7706874||28. Juli 2005||27. Apr. 2010||Cyberonics, Inc.||Stimulating cranial nerve to treat disorders associated with the thyroid gland|
|US7706875||25. Jan. 2007||27. Apr. 2010||Cyberonics, Inc.||Modulation of drug effects by vagus nerve stimulation|
|US7720540||22. Jan. 2007||18. Mai 2010||Enteromedics, Inc.||Pancreatitis treatment|
|US7729771||13. Aug. 2007||1. Juni 2010||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US7747322||12. Okt. 2005||29. Juni 2010||Intrapace, Inc.||Digestive organ retention device|
|US7756582||21. Okt. 2005||13. Juli 2010||Intrapace, Inc.||Gastric stimulation anchor and method|
|US7801601||27. Jan. 2006||21. Sept. 2010||Cyberonics, Inc.||Controlling neuromodulation using stimulus modalities|
|US7803195||31. Mai 2005||28. Sept. 2010||Mayo Foundation For Medical Education And Research||Obesity treatment and device|
|US7822486||17. Aug. 2005||26. Okt. 2010||Enteromedics Inc.||Custom sized neural electrodes|
|US7833279||12. Nov. 2004||16. Nov. 2010||Enteromedics Inc.||Pancreatic exocrine secretion diversion apparatus and method|
|US7835796||29. Apr. 2005||16. Nov. 2010||Cyberonics, Inc.||Weight loss method and device|
|US7837719||9. Mai 2003||23. Nov. 2010||Daemen College||Electrical stimulation unit and waterbath system|
|US7840280||27. Juli 2005||23. Nov. 2010||Cyberonics, Inc.||Cranial nerve stimulation to treat a vocal cord disorder|
|US7844338||30. Juni 2004||30. Nov. 2010||Enteromedics Inc.||High frequency obesity treatment|
|US7856273||28. Juli 2005||21. Dez. 2010||Cyberonics, Inc.||Autonomic nerve stimulation to treat a gastrointestinal disorder|
|US7869867||27. Okt. 2006||11. Jan. 2011||Cyberonics, Inc.||Implantable neurostimulator with refractory stimulation|
|US7869884||26. Apr. 2007||11. Jan. 2011||Cyberonics, Inc.||Non-surgical device and methods for trans-esophageal vagus nerve stimulation|
|US7869885||28. Apr. 2006||11. Jan. 2011||Cyberonics, Inc||Threshold optimization for tissue stimulation therapy|
|US7899540||29. Apr. 2005||1. März 2011||Cyberonics, Inc.||Noninvasively adjustable gastric band|
|US7904175||26. Apr. 2007||8. März 2011||Cyberonics, Inc.||Trans-esophageal vagus nerve stimulation|
|US7957796||28. Okt. 2005||7. Juni 2011||Cyberonics, Inc.||Using physiological sensor data with an implantable medical device|
|US7962214||27. Juli 2007||14. Juni 2011||Cyberonics, Inc.||Non-surgical device and methods for trans-esophageal vagus nerve stimulation|
|US7974701||27. Apr. 2007||5. Juli 2011||Cyberonics, Inc.||Dosing limitation for an implantable medical device|
|US7979127||25. Mai 2010||12. Juli 2011||Intrapace, Inc.||Digestive organ retention device|
|US7986995||22. Jan. 2007||26. Juli 2011||Enteromedics Inc.||Bulimia treatment|
|US8010204||11. März 2010||30. Aug. 2011||Enteromedics Inc.||Nerve blocking for treatment of gastrointestinal disorders|
|US8027718||7. März 2006||27. Sept. 2011||Mayo Foundation For Medical Education And Research||Regional anesthetic|
|US8032223||1. Okt. 2009||4. Okt. 2011||Intrapace, Inc.||Randomized stimulation of a gastrointestinal organ|
|US8046085||25. Okt. 2011||Enteromedics Inc.||Controlled vagal blockage therapy|
|US8095218||13. Juli 2006||10. Jan. 2012||Betastim, Ltd.||GI and pancreatic device for treating obesity and diabetes|
|US8103349||15. Dez. 2009||24. Jan. 2012||Enteromedics Inc.||Neural electrode treatment|
|US8150508||29. März 2007||3. Apr. 2012||Catholic Healthcare West||Vagus nerve stimulation method|
|US8160695||17. Apr. 2012||The Invention Science Fund I, Llc||System for chemical modulation of neural activity|
|US8165668||24. Apr. 2012||The Invention Science Fund I, Llc||Method for magnetic modulation of neural conduction|
|US8165669||24. Apr. 2012||The Invention Science Fund I, Llc||System for magnetic modulation of neural conduction|
|US8170658||15. Febr. 2008||1. Mai 2012||The Invention Science Fund I, Llc||System for electrical modulation of neural conduction|
|US8170659||1. Mai 2012||The Invention Science Fund I, Llc||Method for thermal modulation of neural activity|
|US8170660||1. Mai 2012||The Invention Science Fund I, Llc||System for thermal modulation of neural activity|
|US8180446||5. Dez. 2007||15. Mai 2012||The Invention Science Fund I, Llc||Method and system for cyclical neural modulation based on activity state|
|US8180447||18. Juni 2008||15. Mai 2012||The Invention Science Fund I, Llc||Method for reversible chemical modulation of neural activity|
|US8195287||15. Febr. 2008||5. Juni 2012||The Invention Science Fund I, Llc||Method for electrical modulation of neural conduction|
|US8204603||25. Apr. 2008||19. Juni 2012||Cyberonics, Inc.||Blocking exogenous action potentials by an implantable medical device|
|US8219188||29. März 2007||10. Juli 2012||Catholic Healthcare West||Synchronization of vagus nerve stimulation with the cardiac cycle of a patient|
|US8233976||18. Juni 2008||31. Juli 2012||The Invention Science Fund I, Llc||System for transdermal chemical modulation of neural activity|
|US8239027||12. März 2010||7. Aug. 2012||Intrapace, Inc.||Responsive gastric stimulator|
|US8239028||24. Apr. 2009||7. Aug. 2012||Cyberonics, Inc.||Use of cardiac parameters in methods and systems for treating a chronic medical condition|
|US8255057||29. Jan. 2009||28. Aug. 2012||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8280505||10. März 2009||2. Okt. 2012||Catholic Healthcare West||Vagus nerve stimulation method|
|US8306627||23. Mai 2011||6. Nov. 2012||Cyberonics, Inc.||Dosing limitation for an implantable medical device|
|US8337404||1. Okt. 2010||25. Dez. 2012||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8364269||19. Okt. 2009||29. Jan. 2013||Intrapace, Inc.||Responsive gastric stimulator|
|US8369952||7. Juli 2011||5. Febr. 2013||Enteromedics, Inc.||Bulimia treatment|
|US8372158||22. Sept. 2010||12. Febr. 2013||Enteromedics, Inc.||Obesity treatment and device|
|US8382667||29. Apr. 2011||26. Febr. 2013||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8391970||26. Aug. 2008||5. März 2013||The Feinstein Institute For Medical Research||Devices and methods for inhibiting granulocyte activation by neural stimulation|
|US8412338||17. Nov. 2009||2. Apr. 2013||Setpoint Medical Corporation||Devices and methods for optimizing electrode placement for anti-inflamatory stimulation|
|US8414559||7. Mai 2009||9. Apr. 2013||Rainbow Medical Ltd.||Gastroretentive duodenal pill|
|US8417344||24. Okt. 2008||9. Apr. 2013||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8452387||20. Sept. 2010||28. Mai 2013||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8457747||20. Okt. 2008||4. Juni 2013||Cyberonics, Inc.||Neurostimulation with signal duration determined by a cardiac cycle|
|US8483830||3. Apr. 2009||9. Juli 2013||Enteromedics Inc.||Methods and systems for glucose regulation|
|US8509906||9. Juli 2012||13. Aug. 2013||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8538533||19. Okt. 2011||17. Sept. 2013||Enteromedics Inc.||Controlled vagal blockage therapy|
|US8538542||21. Juli 2011||17. Sept. 2013||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US8562536||29. Apr. 2010||22. Okt. 2013||Flint Hills Scientific, Llc||Algorithm for detecting a seizure from cardiac data|
|US8565867||25. Jan. 2008||22. Okt. 2013||Cyberonics, Inc.||Changeable electrode polarity stimulation by an implantable medical device|
|US8571643||16. Sept. 2010||29. Okt. 2013||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8612002||23. Dez. 2010||17. Dez. 2013||Setpoint Medical Corporation||Neural stimulation devices and systems for treatment of chronic inflammation|
|US8615309||29. März 2007||24. Dez. 2013||Catholic Healthcare West||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US8617095||5. Okt. 2010||31. Dez. 2013||Enteromedics Inc.||Pancreatic exocrine secretion diversion apparatus and method|
|US8630706||13. März 2012||14. Jan. 2014||The Invention Science Fund I, Llc||Method and system for reversible chemical modulation of neural activity|
|US8641646||30. Juli 2010||4. Febr. 2014||Cyberonics, Inc.||Seizure detection using coordinate data|
|US8649871||30. Apr. 2010||11. Febr. 2014||Cyberonics, Inc.||Validity test adaptive constraint modification for cardiac data used for detection of state changes|
|US8660647||28. Juli 2005||25. Febr. 2014||Cyberonics, Inc.||Stimulating cranial nerve to treat pulmonary disorder|
|US8660666||10. März 2009||25. Febr. 2014||Catholic Healthcare West||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US8679009||15. Juni 2010||25. März 2014||Flint Hills Scientific, Llc||Systems approach to comorbidity assessment|
|US8684921||15. Mai 2012||1. Apr. 2014||Flint Hills Scientific Llc||Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis|
|US8696543||14. Okt. 2008||15. Apr. 2014||Kirk Promotion Ltd.||Method for controlling flow of intestinal contents in a patient's intestines|
|US8700163||29. Apr. 2005||15. Apr. 2014||Cyberonics, Inc.||Cranial nerve stimulation for treatment of substance addiction|
|US8715181||27. Apr. 2012||6. Mai 2014||Intrapace, Inc.||Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments|
|US8725239||25. Apr. 2011||13. Mai 2014||Cyberonics, Inc.||Identifying seizures using heart rate decrease|
|US8729129||24. März 2005||20. Mai 2014||The Feinstein Institute For Medical Research||Neural tourniquet|
|US8738126||10. März 2009||27. Mai 2014||Catholic Healthcare West||Synchronization of vagus nerve stimulation with the cardiac cycle of a patient|
|US8768469||6. Aug. 2009||1. Juli 2014||Enteromedics Inc.||Systems for regulation of blood pressure and heart rate|
|US8768471||3. März 2013||1. Juli 2014||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8788034||9. Mai 2012||22. Juli 2014||Setpoint Medical Corporation||Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation|
|US8798754||10. März 2008||5. Aug. 2014||Venturi Group, Llc||Neural blocking therapy|
|US8825164||7. Juni 2011||2. Sept. 2014||Enteromedics Inc.||Neural modulation devices and methods|
|US8827912||27. Apr. 2010||9. Sept. 2014||Cyberonics, Inc.||Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters|
|US8831732||30. Apr. 2010||9. Sept. 2014||Cyberonics, Inc.||Method, apparatus and system for validating and quantifying cardiac beat data quality|
|US8849409||3. März 2013||30. Sept. 2014||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8849410||5. Apr. 2013||30. Sept. 2014||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8852100||25. Febr. 2013||7. Okt. 2014||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8855767||15. Nov. 2013||7. Okt. 2014||Setpoint Medical Corporation||Neural stimulation devices and systems for treatment of chronic inflammation|
|US8862233||4. Febr. 2013||14. Okt. 2014||Enteromedics Inc.||Electrode band system and methods of using the system to treat obesity|
|US8874218||23. Apr. 2013||28. Okt. 2014||Cyberonics, Inc.||Neurostimulation with signal duration determined by a cardiac cycle|
|US8886339||9. Juni 2010||11. Nov. 2014||Setpoint Medical Corporation||Nerve cuff with pocket for leadless stimulator|
|US8888702||3. Dez. 2012||18. Nov. 2014||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8911393||6. Febr. 2013||16. Dez. 2014||Mayo Foundation For Medical Education And Research||Obesity treatment and device|
|US8914114||17. Nov. 2004||16. Dez. 2014||The Feinstein Institute For Medical Research||Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation|
|US8934976||30. Sept. 2011||13. Jan. 2015||Intrapace, Inc.||Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors|
|US8945006||24. Febr. 2014||3. Febr. 2015||Flunt Hills Scientific, LLC||Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis|
|US8948855||21. Mai 2013||3. Febr. 2015||Flint Hills Scientific, Llc||Detecting and validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8972013||25. März 2011||3. März 2015||Cyberonics, Inc.||Using physiological sensor data with an implantable medical device|
|US8989858||18. Juni 2008||24. März 2015||The Invention Science Fund I, Llc||Implant system for chemical modulation of neural activity|
|US8996116||1. Nov. 2010||31. März 2015||Setpoint Medical Corporation||Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction|
|US9014802||9. Dez. 2013||21. Apr. 2015||The Invention Science Fund I, Llc||Method and system for modulating neural activity in a limb|
|US9020582||30. Sept. 2013||28. Apr. 2015||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US9020591||9. Dez. 2013||28. Apr. 2015||The Invention Science Fund I, Llc||Method and system for ultrasonic neural modulation in a limb|
|US9020592||9. Dez. 2013||28. Apr. 2015||The Invention Science Fund I, Llc||Method and system for blocking nerve conduction|
|US9050469||24. Nov. 2004||9. Juni 2015||Flint Hills Scientific, Llc||Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals|
|US9095711||30. Juni 2014||4. Aug. 2015||Enteromedics Inc.||Systems for regulation of blood pressure and heart rate|
|US9108041||25. Nov. 2013||18. Aug. 2015||Dignity Health||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US20040167583 *||6. Jan. 2004||26. Aug. 2004||Enteromedics, Inc.||Electrode band apparatus and method|
|US20040172085 *||29. Sept. 2003||2. Sept. 2004||Beta Medical, Inc.||Nerve stimulation and conduction block therapy|
|US20040172086 *||29. Sept. 2003||2. Sept. 2004||Beta Medical, Inc.||Nerve conduction block treatment|
|US20040172088 *||6. Jan. 2004||2. Sept. 2004||Enteromedics, Inc.||Intraluminal electrode apparatus and method|
|US20050065571 *||23. Sept. 2004||24. März 2005||Imran Mir A.||Responsive gastric stimulator|
|US20050070970 *||12. Jan. 2004||31. März 2005||Knudson Mark B.||Movement disorder stimulation with neural block|
|US20050090873 *||22. Okt. 2003||28. Apr. 2005||Imran Mir A.||Gastrointestinal stimulation device|
|US20050222226 *||22. Apr. 2005||6. Okt. 2005||Sumitomo Pharmaceuticals Company, Limited||Five-membered cyclic compounds|
|US20050273060 *||31. Mai 2005||8. Dez. 2005||Mayo Foundation For Medical Education And Research||Obesity treatment and device|
|US20060020277 *||19. Juli 2005||26. Jan. 2006||Gostout Christopher J||Gastric reshaping devices and methods|
|US20060020298 *||23. Aug. 2004||26. Jan. 2006||Camilleri Michael L||Systems and methods for curbing appetite|
|US20060070334 *||27. Sept. 2004||6. Apr. 2006||Blue Hen, Llc||Sidewall plank for constructing a trailer and associated trailer sidewall construction|
|US20060106332 *||12. Nov. 2004||18. Mai 2006||Enteromedics Inc.||Pancreatic exocrine secretion diversion apparatus and method|
|US20060200208 *||29. Apr. 2005||7. Sept. 2006||Cyberonics, Inc.||Cranial nerve stimulation for treatment of substance addiction|
|US20060247719 *||29. Apr. 2005||2. Nov. 2006||Cyberonics, Inc.||Weight loss method and advice|
|US20060247721 *||29. Apr. 2005||2. Nov. 2006||Cyberonics, Inc.||Identification of electrodes for nerve stimulation in the treatment of eating disorders|
|US20060247722 *||29. Apr. 2005||2. Nov. 2006||Cyberonics, Inc.||Noninvasively adjustable gastric band|
|US20070016262 *||11. Apr. 2006||18. Jan. 2007||Betastim, Ltd.||Gi and pancreatic device for treating obesity and diabetes|
|US20070027484 *||28. Juli 2005||1. Febr. 2007||Cyberonics, Inc.||Autonomic nerve stimulation to treat a pancreatic disorder|
|US20070027492 *||28. Juli 2005||1. Febr. 2007||Cyberonics, Inc.||Autonomic nerve stimulation to treat a gastrointestinal disorder|
|US20070027504 *||27. Juli 2005||1. Febr. 2007||Cyberonics, Inc.||Cranial nerve stimulation to treat a hearing disorder|
|US20090149797 *||18. Juni 2008||11. Juni 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||System for reversible chemical modulation of neural activity|
|US20090210019 *||13. Febr. 2009||20. Aug. 2009||Dennis Dong-Won Kim||Treatment of excess weight by neural downregulation in combination with compositions|
|US20110087337 *||12. Apr. 2010||14. Apr. 2011||Peter Forsell||Apparatus for controlling flow in a bodily organ|
|EP2275171A2||1. Aug. 2006||19. Jan. 2011||Enteromedics Inc.||Apparatus for neural electrode treatment|
|WO2007021534A1||1. Aug. 2006||22. Febr. 2007||Enteromedics Inc||Neural electrode treatment|
|Internationale Klassifikation||A61N1/36, A61N1/34, A61N1/05, A61N1/32|
|Unternehmensklassifikation||A61N1/36071, A61N1/36007, A61N1/321, A61N1/05, A61N1/3606, A61N1/0551, A61N1/36053|
|Europäische Klassifikation||A61N1/36Z, A61N1/36Z3C, A61N1/36, A61N1/05, A61N1/32B, A61N1/36B|
|29. Sept. 2003||AS||Assignment|
Owner name: BETA MEDICAL, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNUDSON, MARK B.;WILSON, RICHARD R.;TWEDEN, KATHERINE S.;AND OTHERS;REEL/FRAME:014576/0913
Effective date: 20030929
|23. Jan. 2004||AS||Assignment|
Owner name: ENTEROMEDICS INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:BETA MEDICAL, INC.;REEL/FRAME:014970/0774
Effective date: 20031114